Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

But KRAS is no space station. It’s a lethal, misshapen protein that jumpstarts a pathway that drives almost a quarter of all cancers, and it has baffled scientists who have spent almost four ...

The EGFR pathway has an important role in modulating ... Given the focus on personalized cancer care in the context of KRAS mutation status in colorectal cancer, the clinical community will ...

Ferroptosis offers new strategies to combat treatment resistance in digestive tract cancers, enhancing the efficacy of ...

SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Resistance to therapies targeting the epidermal growth factor receptor (EGFR) pathway also appears to be ... effectively sensitizes KRAS-mutant colorectal cancer cells to treatment, highlighting ...

and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs ...

Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined ...